LA JOLLA, Calif., April 15 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc., (OTC Bulletin Board: DSKA), a biotechnology company developing medical products based on adenosine 5'-triphosphate (ATP) and P2 receptor-related technologies, announced today that it has scheduled its 2008 Annual Meeting of Shareholders for 10AM (Eastern) on June 27, 2008.
The Annual Meeting will be held at the law offices of Fish and Richardson, Citigroup Center, 153 East 53rd Street, 52nd Floor, New York, NY 10022.
At the Annual Meeting, Duska shareholders will be asked to approve the election of directors and the reappointment of Duska's independent auditors. The voting record date for determination of shareholders entitled to vote at the meeting has been set at the close of business on May 2, 2008. Dr. James Kuo, Duska's Chairman and CEO, will be providing an update on the company's drug development programs and answering any questions.
About Duska Therapeutics, Inc.
Duska Therapeutics, Inc., based in La Jolla, California, is a biotechnology company focused on the development of medical products related to adenosine 5'-triphosphate (ATP) and P2 receptors (P2R). Duska owns or has exclusive license rights to a number of proprietary products in various stages of development. Additional information is available at http://www.duskatherapeutics.com.
Forward-looking statements
This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Duska intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Duska are forward-looking statements, such as the characterization of Duska as an emerging biotechnology company. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Additional uncertainties and risks are described in Duska's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Duska on the date hereof. Duska undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Duska Therapeutics, Inc.
